New and improved glucocorticoid receptor ligands

Expert Opinion on Investigational Drugs

Volumn 14, Issue 12, 2005, Pages 1527-1545

  Miner, Jeffrey N ^a   Hong, Mei Hua ^a   Negro Vilar, Andrés ^a  

^a LIGAND PHARMACEUTICALS INC   (United States)

Author keywords

Glucocorticoid; Osteoporosis; Selective GR modulators

Indexed keywords

4 (2,3 DIHYDROBENZOFURAN 7 YL) 2 HYDROXY 3,3 DIMETHYL N (4 METHYL 1 OXO 2,3 BENZOXAZIN 6 YL) 2 TRIFLUOROMETHYLBUTANAMIDE; A 276575; AL 438; BECLOMETASONE DIPROPIONATE; BUDESONIDE; BUTYROLACTONE; DEFLAZACORT; DIHYDROBENZOFURAN DERIVATIVE; FLUTICASONE PROPIONATE; GLUCOCORTICOID; GLUCOCORTICOID RECEPTOR; GLUCOCORTICOID RECEPTOR AGONIST; GLUCOCORTICOID RECEPTOR ANTAGONIST; HYDROCORTISONE PLUS NITRIC OXIDE; LIGAND; LIPOSOME; LOTEPREDNOL ETABONATE; MIFEPRISTONE; NCX 1010; NEW DRUG; NITRIC OXIDE; NITRIC OXIDE PLUS PREDNISOLONE; ONAPRISTONE; PHENYLPYRAZOLE DERIVATIVE; PREDNISOLONE; PYRAZOLE DERIVATIVE; QUINOLINE DERIVATIVE; RU 24858; RU 40066; SELECTIVE GLUCOCORTICOID RECEPTOR MODULATOR; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ADRENAL SUPPRESSION; ANTIINFLAMMATORY ACTIVITY; ASTHENIA; ASTHMA; BONE INJURY; BONE NECROSIS; BONE REMODELING; CELL PROLIFERATION; CLINICAL TRIAL; CORTICOSTEROID INDUCED OSTEOPOROSIS; CUSHING DISEASE; DIABETES MELLITUS; DRUG EFFICACY; DRUG FORMULATION; DRUG MECHANISM; DRUG METABOLISM; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG SELECTIVITY; DRUG STRUCTURE; FRAGILITY FRACTURE; GLUCOSE INTOLERANCE; GROWTH HORMONE DEFICIENCY; HUMAN; HYPERGLYCEMIA; HYPERTENSION; IMMUNE DEFICIENCY; IMMUNOMODULATION; INFECTION COMPLICATION; INFLAMMATORY DISEASE; INSULIN RESISTANCE; LEUKOPENIA; LONG TERM CARE; MOON FACE; MUSCLE ATROPHY; MUSCLE WEAKNESS; MYOPATHY; NEUROSIS; OBESITY; PSYCHOSIS; REVIEW; RHEUMATOID ARTHRITIS; SIDE EFFECT; WEIGHT GAIN; WOUND HEALING IMPAIRMENT;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTINEOPLASTIC AGENTS; DRUG DELIVERY SYSTEMS; DRUGS, INVESTIGATIONAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LIGANDS; RECEPTORS, GLUCOCORTICOID;

EID: 28644436807     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.14.12.1527     Document Type: Review

References (132)

1. KIRWAN JR, BALINT G, SZEBENYI B: Anniversary: 50 years of glucocorticoid treatment in rheumatoid arthritis. Rheumatology (1999) 38:100-102.
2. NEECK G: Fifty years of experience with cortisone therapy in the study and treatment of rheumatoid arthritis. Ann. NY Acad. Sci. (2002) 966:28-38.
3. JOELS M, VREUGDENHIL E: Corticosteroids in the brain. Cellular and molecular actions. Mol. Neurobiol. (1998) 17:87-108.
4. BODINE PV, LITWACK G: The glucocorticoid receptor and its endogenous regulators. Receptor (1990) 1:83-119.
5. McEWEN BS, COIRINI H, SCHUMACHER M: Steroid effects on neuronal activity: when is the genome involved? Ciba Found Symp. (1990) 153:3-12 (Discussion 12-21).
6. WANG W, XING BR, CHEN YZ: [Fast modulation of glutamate and GABA receptor-mediate electrophysiological responses by glucocorticoid]. Sheng Li Hsueh Pao (1996) 48:551-556.
7. LU NZ, CIDLOWSKI JA: The origin and functions of multiple human glucocorticoid receptor isoforms. Ann. NY Acad. Sci. (2004) 1024:102-123.
8. GALIGNIANA MD, SCRUGGS JL, HERRINGTON J et al.: Heat shock protein 90-dependent (geldanamycin-inhibited) movement of the glucocorticoid receptor through the cytoplasm to the nucleus requires intact cytoskeleton. Mol. Endocrinol. (1998) 12:1903-1913.
9. JENKINS BD, PULLEN CB, DARIMONT BD: Novel glucocorticoid receptor coactivator effector mechanisms. Trends Endocrinol. Metab. (2001) 12:122-126.
10. BOUMPAS DT, CHROUSOS GP, WILDER RL, CUPPS TR, BALOW JE: Glucocorticoid therapy for immune-mediated diseases: basic and clinical correlates. Ann. Intern. Med. (1993) 119:1198-1208.
11. ORTH DN, KOVACS WJ: The adrenal cortex. In: Series the adrenal cortex. Wilson JD, Foster DW, Kronenberg HM, Larsen PR (Eds), W. B. Saunders Company, Philadelphia, USA (1998):517.
12. HEUCK C, HEICKENDORFF L, WOLTHERS OD: A randomised controlled trial of short term growth and collagen turnover in asthmatics treated with inhaled formoterol and budesonide. Arch. Dis. Child. (2000) 83:334-339.
13. DEEG HJ, HENSLEE-DOWNEY PJ: Management of acute graft-versus-host disease. Bone Marrow Transplant (1990) 6:1-8.
14. AXELROD L: Side effects of glucocorticoid therapy. In: Series side effects of glucocorticoid therapy. Schleimer RP, Claman HN, Oronsky AL (Eds), Academic Press, Inc., San Diego, USA (1989):377-408.
15. TBCDS: Acute adverse reactions to prednisone in relation to dosage. Clin. Pharmacol. Ther. (1972) 13:694-698.
16. BITRAN D, SHIEKH M, DOWD JA, DUGAN MM, RENDA P: Corticosterone is permissive to the anxiolytic effect that results from the blockade of hippocampal mineralocorticoid receptors. Pharmacol. Biochem. Behav. (1998) 60:879-887.
17. TAPPY L, RANDIN D, VOLLENWEIDER P et al.: Mechanisms of dexamethasone-induced insulin resistance in healthy humans. J. Clin. Endocrinol. Metab. (1994) 79:1063-1069.
18. LAAKSO M, EDELMAN SV, OLEFSKY JM, BRECHTEL G, WALLACE P, BARON AD: Kinetics of in vivo muscle insulin-mediated glucose uptake in human obesity. Diabetes (1990) 39:965-974.
19. GRANNER DK, SASAKI K, CHU D: Multihormonal regulation of phosphoenolpyruvate carboxykinase gene transcription. The dominant role of insulin. Ann. NY Acad. Sci. (1986) 478:175-190.
20. CONN HO, POYNARD T: Corticosteroids and peptic ulcer: meta-analysis of adverse events during steroid therapy. J. Intern. Med. (1994) 236:619-632.
21. BRINDLEY DN, MCCANN BS, NIAURA R, STONEY CM, SUAREZ EC: Stress and lipoprotein metabolism: modulators and mechanisms. Metabolism (1993) 42:3-15.
22. BREM AS: Insights into glucocorticoid-associated hypertension. Am. J. Kidney Dis. (2001) 37:1-10.
23. GONZALEZ-CADAVID NF, BHASIN S: Role of myostatin in metabolism. Curr. Opin. Clin. Nutr. Metab. Care (2004) 7:451-457.
24. DIETHELM AG: Surgical management of complications of steroid therapy. Ann. Surg. (1977) 185:251-263.
25. ANSTEAD GM: Steroids, retinoids, and wound healing. Adv. Wound Care (1998) 11:277-285.
26. AUTIO P, OIKARINEN A, MELKKO J, RISTELI J, RISTELI L: Systemic glucocorticoids decrease the synthesis of type I and type III collagen in human skin in vivo, whereas isotretinoin treatment has little effect. Br. J. Dermatol. (1994) 131:660-663.
27. BRAUCHLE M, FASSLER R, WERNER S: Suppression of keratinocyte growth factor expression by glucocorticoids in vitro and during wound healing. J. Invest. Dermatol. (1995) 105:579-584.
28. LUKERT BP, KREAM BE: Clinical and basic aspects of glucocorticoid action in bone. In: Series clinical and basic aspects of glucocorticoid action in bone. Academic Press, Inc., Philadelphia, USA (1996).
29. RALSTON SH: Pathogenesis and management of corticosteroid-induced osteoporosis. Curr. Opin. Onc. Endo. Metab. Invest. Drugs (1999) 1:25-30.
30. VAN STAA TP, LEUFKENS HG, ABENHAIM L, ZHANG B, COOPER C: Oral corticosteroids and fracture risk: relationship to daily and cumulative doses. Rheumatology (2000) 39:1383-1389.
31. PATSCHAN D, LODDENKEMPER K, BUTTGEREIT F: Molecular mechanisms of glucocorticoid-induced osteoporosis. Bone (2001) 29:498-505.
32. DEMPSTER DW: Bone histomorphometry in glucocorticoid-induced osteoporosis. J. Bone Miner. Res. (1989) 4:137-141.
33. CENTRELLA M, ROSEN V, WOZNEY JM, CASINGHINO SR, McCARTHY TL: Opposing effects by glucocorticoid and bone morphogenetic protein-2 in fetal rat bone cell cultures. J. Cell. Biochem. (1997) 67:528-540.
34. CHANG DJ, JI C, KIM KK, CASINGHINO S, McCARTHY TL, CENTRELLA M: Reduction in transforming growth factor β receptor I expression and transcription factor CBFa1 on bone cells by glucocorticoid. J. Biol. Chem. (1998) 273:4892-4896.
35. SHI XM, BLAIR HC, YANG X, McDONALD JM, CAO X: Tandem repeat of C/EBP binding sites mediates PPARγ2 gene transcription in glucocorticoid-induced adipocyte differentiation. J. Cell. Biochem. (2000) 76:518-527.
36. McCULLOCH CA, TENENBAUM HC: Dexamethasone induces proliferation and terminal differentiation of osteogenic cells in tissue culture. Anat. Rec. (1986) 215:397-402.
37. GRONOWICZ GA, DEROME ME: Synthetic peptide containing Arg-Gly-Asp inhibits bone formation and resorption in a mineralizing organ culture system of fetal rat parietal bones. J. Bone Miner. Res. (1994) 9:193-201.
38. 1-integrin in bone: effect of glucocorticoids and insulin-like growth factor I on integrins and osteocyte formation. J. Histochem. Cytochem. (1995) 43:1085-1096.
39. DEFRANCO DJ, LIAN JB, GLOWACKI J: Differential effects of glucocorticoid on recruitment and activity of osteoclasts induced by normal and osteocalcin-deficient bone implanted in rats. Endocrinology (1992) 131:114-121.
40. HOFBAUER LC, KHOSLA S, DUNSTAN CR, LACEY DL, BOYLE WJ, RIGGS BL: The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption. J. Bone Miner. Res. (2000) 15:2-12.
41. SASAKI N, KUSANO E, ANDO Y, YANO K, TSUDA E, ASANO Y: Glucocorticoid decreases circulating osteoprotegerin (OPG): possible mechanism for glucocorticoid induced osteoporosis. Nephrol. Dial. Transplant. (2001) 16:479-482.
42. MORRISON NA, SHINE J, FRAGONAS JC, VERKEST V, McMENEMY ML, EISMAN JA: 1,25-dihydroxyvitamin D-responsive element and glucocorticoid repression in the osteocalcin gene. Science (1989) 246:1158-1161.
43. DELANY AM, GABBITAS BY, CANALIS E: Cortisol downregulates osteoblast α1 (I) procollagen mRNA by transcriptional and posttranscriptional mechanisms. J. Cell. Biochem. (1995) 57:488-494.
44. SUBRAMANIAM M, COLVARD D, KEETING PE, RASMUSSEN K, RIGGS BL, SPELSBERG TC: Glucocorticoid regulation of alkaline phosphatase, osteocalcin, and proto-oncogenes in normal human osteoblast-like cells. J. Cell. Biochem. (1992) 50:411-424.
45. GRONOWICZ GA, DEROME ME, McCARTHY MB: Glucocorticoids inhibit fibronectin synthesis and messenger ribonucleic acid levels in cultured fetal rat parietal bones. Endocrinology (1991) 128:1107-1114.
46. 1 integrins. J. Bone Joint Surg. Am. (1995) 77:396-404.
47. ABBADIA Z, AMIRAL J, TRZECIAK MC, DELMAS PD, CLEZARDIN P: The growth-supportive effect of thrombospondin (TSP1) and the expression of TSP1 by human MG-63 osteoblastic cells are both inhibited by dexamethasone. FEBS Lett. (1993) 335:161-166.
48. WEINSTEIN RS, MANOLAGAS SC: Apoptosis and osteoporosis. Am. J. Med. (2000) 108:153-164.
49. REID IR, VEALE AG, FRANCE JT: Glucocorticoid osteoporosis. J. Asthma (1994) 31:7-18.
50. MARTENS HF, SHEETS PK, TENOVER JS, DUGOWSON CE, BREMNER WJ, STARKEBAUM G: Decreased testosterone levels in men with rheumatoid arthritis: effect of low dose prednisone therapy. J. Rheumatol. (1994) 21:1427-1431.
51. WIMALAWANSA SJ: Prevention and treatment of osteoporosis: efficacy of combination of hormone replacement therapy with other antiresorptive agents. J. Clin. Densitom. (2000) 3:187-201.
52. HAHN TJ, HALSTEAD LR, BARAN DT: Effects off short term glucocorticoid administration on intestinal calcium absorption and circulating vitamin D metabolite concentrations in man. J. Clin. Endocrinol. Metab. (1981) 52:111-115.
53. AARDEN EM, BURGER EH, NIJWEIDE PJ: Function of osteocytes in bone. J. Cell. Biochem. (1994) 55:287-299.
54. ZAMAN G, PITSILLIDES AA, RAWLINSON SC et al.: Mechanical strain stimulates nitric oxide production by rapid activation of endothelial nitric oxide synthase in osteocytes. J. Bone Miner. Res. (1999) 14:1123-1131.
55. CHANG CC, GREENSPAN A, GERSHWIN ME: Osteonecrosis: current perspectives on pathogenesis and treatment. Semin. Arthritis Rheum. (1993) 23:47-69.
56. CHERNETSKY SG, MONT MA, LAPORTE DM, JONES LC, HUNGERFORD DS, McCARTHY EF: Pathologic features in steroid and nonsteroid associated osteonecrosis. Clin. Orthop. (1999):149-161.
57. MANKIN HJ: Nontraumatic necrosis of bone (osteonecrosis). N. Engl. J. Med. (1992) 326:1473-1479.
58. WARMAN M, BOSKEY AL: Effect of high levels of corticosteroids on the lipids of the long bones of the mature rabbit. Metab. Bone Dis. Relat. Res. (1983) 4:319-324.
59. WEINSTEIN RS, NICHOLAS RW, MANOLAGAS SC: Apoptosis of osteocytes in glucocorticoid-induced osteonecrosis of the hip. J. Clin. Endocrinol. Metab. (2000) 85:2907-2912.
60. EBERHARDT AW, YEAGER-JONES A, BLAIR HC: Regional trabecular bone matrix degeneration and osteocyte death in femora of glucocorticoid- treated rabbits. Endocrinology (2001) 142:1333-1340.
61. ISHIDA Y, HEERSCHE JN: Glucocorticoid-induced osteoporosis: both in vivo and in vitro concentrations of glucocorticoids higher than physiological levels attenuate osteoblast differentiation. J. Bone Miner. Res. (1998) 13:1822-1826.
62. WEINSTEIN RS, JILKA RL, PARFITT AM, MANOLAGAS SC: Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids. Potential mechanisms of their deleterious effects on bone. J. Clin. Invest. (1998) 102:274-282.
63. KIM CH, CHENG SL, KIM GS: Effects of dexamethasone on proliferation, activity, and cytokine secretion of normal human bone marrow stromal cells: possible mechanisms of glucocorticoid-induced bone loss. J. Endocrinol. (1999) 162:371-379.
64. MINER JN, YAMAMOTO KR: Regulatory crosstalk at composite response elements. Trends Biochem. Sci. (1991) 16:423-426.
65. DIAMOND MI, MINER JN, YOSHINAGA SK, YAMAMOTO KR: Transcription factor interactions: selectors of positive or negative regulation from a single DNA element. Science (1990) 249:1266-1272.
66. MINER JN, YAMAMOTO KR: The basic region of AP-1 specifies glucocorticoid receptor activity at a composite response element. Genes Dev. (1992) 6:2491-2501.
67. MINER JN, DIAMOND MI, YAMAMOTO KR: Joints in the regulatory lattice: composite regulation by steroid receptor-AP1 complexes. Cell Growth Differ. (1991) 2:525-530.
68. McKAY LI, CIDLOWSKI JA: Cross-talk between nuclear factor-κB and the steroid hormone receptors: mechanisms of mutual antagonism. Mol. Endocrinol. (1998) 12:45-56.
69. BARNES PJ, ADCOCK IM: How do corticosteroids work in asthma? Ann. Intern. Med. (2003) 139:359-370.
70. JIN JY, ALMON RR, DUBOIS DC, JUSKO WJ: Modeling of corticosteroid pharmacogenomics in rat liver using gene microarrays. J. Pharmacol. Exp. Ther. (2003) 307:93-109.
71. ALLAN GF, TSAI SY, O'MALLEY BW, TSAI MJ: Steroid hormone receptors and in vitro transcription. Bioessays (1991) 13:73-78.
72. HONG H, DARIMONT BD, MA H, YANG L, YAMAMOTO KR, STALLCUP MR: An additional region of coactivator GRIP1 required for interaction with the hormone-binding domains of a subset of nuclear receptors. J. Biol. Chem. (1999) 274:3496-3502.
73. SMITH CL, ONATE SA, TSAI MJ, O'MALLEY BW: CREB binding protein acts synergistically with steroid receptor coactivator-1 to enhance steroid receptor-dependent transcription. Proc. Natl. Acad. Sci. USA (1996) 93:8884-8888.
74. DARIMONT BD, WAGNER RL, APRILETTI JW et al.: Structure and specificity of nuclear receptor-coactivator interactions. Genes Dev. (1998) 12:3343-3356.
75. LIU J, DEFRANCO DB: Chromatin recycling of glucocorticoid receptors: implications for multiple roles of heat shock protein 90. Mol. Endocrinol. (1999) 13:355-365.
76. PHILLIPS SJ: Physiology of wound healing and surgical wound care. Asaio. J. (2000) 46:S2-S5.
77. MOEHREN U, ECKEY M, BANIAHMAD A: Gene repression by nuclear hormone receptors. Essays Biochem. (2004) 40:89-104.
78. BARNES PJ: Anti-inflammatory actions of glucocorticoids: molecular mechanisms. Clin. Sci. (1998) 94:557-572.
79. DE BOSSCHER K, SCHMITZ ML, VANDEN BERGHE W, PLAISANCE S, FIERS W, HAEGEMAN G: Glucocorticoid-mediated repression of nuclear factor-κB-dependent transcription involves direct interference with transactivation. Proc. Natl. Acad. Sci. USA (1997) 94:13504-13509.
80. REICHARDT HM, KAESTNER KH, TUCKERMANN J et al.: DNA binding of the glucocorticoid receptor is not essential for survival [see comments]. Cell (1998) 93:531-541.
81. ZHOU XF, SHEN XQ, SHEMSHEDINI L: Ligand-activated retinoic acid receptor inhibits AP-1 transactivation by disrupting c-Jun/c-Fos dimerization. Mol. Endocrinol. (1999) 13:276-285.
82. MEYER T, GUSTAFSSON JA, CARLSTEDT-DUKE J: Glucocorticoid-dependent transcriptional repression of the osteocalcin gene by competitive binding at the TATA box. DNA Cell Biol. (1997) 16:919-927.
83. DE LANGE P, KOPER JW, HUIZENGA NA et al.: Differential hormone-dependent transcriptional activation and - repression by naturally occurring human glucocorticoid receptor variants. Mol. Endocrinol. (1997) 11:1156-1164.
84. DE BOSSCHER K, VANDEN BERGHE W, HAEGEMAN G: Glucocorticoid repression of AP-1 is not mediated by competition for nuclear coactivators. Mol. Endocrinol. (2001) 15:219-227.
85. HECK S, BENDER K, KULLMANN M, GOTTLICHER M, HERRLICH P, CATO AC: I κB α-independent downregulation of NF-κB activity by glucocorticoid receptor. EMBO J. (1997) 16:4698-4707.
86. RAY A, SIEGEL MD, PREFONTAINE KE, RAY P: Anti-inflammation: direct physical association and functional antagonism between transcription factor NF-κB and the glucocorticoid receptor. Chest (1995) 107:139S.
87. GOTTLICHER M, HECK S, HERRLICH P: Transcriptional cross-talk, the second mode of steroid hormone receptor action. J. Mol. Med. (1998) 76:480-489.
88. NISSEN RM, YAMAMOTO KR: The glucocorticoid receptor inhibits NFκB by interfering with serine-2 phosphorylation of the RNA polymerase II carboxy-terminal domain. Genes Dev. (2000) 14:2239-2314.
89. KASSEL O, SCHNEIDER S, HEILBOCK C, LITFIN M, GOTTLICHER M, HERRLICH P: A nuclear isoform of the focal adhesion LIM-domain protein Trip6 integrates activating and repressing signals at AP-1- and NF-κB-regulated promoters. Genes Dev. (2004) 18:2518-2528.
90. McNALLY JG, MULLER WG, WALKER D, WOLFORD R, HAGER GL: The glucocorticoid receptor: rapid exchange with regulatory sites in living cells. Science (2000) 287:1262-1265.
91. ROGATSKY I, ZAREMBER KA, YAMAMOTO KR: Factor recruitment and TIF2/GRIP1 corepressor activity at a collagenase-3 response element that mediates regulation by phorbol esters and hormones. EMBO J (2001) 20:6071-6083.
92. BRUNA A, NICOLAS M, MUNOZ A, KYRIAKIS JM, CAELLES C: Glucocorticoid receptor-JNK interaction mediates inhibition of the JNK pathway by glucocorticoids. EMBO J. (2003) 22:6035-6044.
93. MALCHOFF CD, MALCHOFF DM: Glucocorticoid resistance and hypersensitivity. Endocrinol. Metab. Clin. North Am. (2005) 34:315-326.
94. KIM MY, BUYON JP, PETRI M, SKOVRON ML, SHORE RE: Equivalence trials in SLE research: issues to consider. Lupus (1999) 8:620-626.
95. CHAVASSIEUX PM, ARLOT ME, ROUX JP et al.: Effects of alendronate on bone quality and remodeling in glucocorticoid- induced osteoporosis: a histomorphometric analysis of transiliac biopsies. J. Bone Miner. Res. (2000) 15:754-762.
96. NIEMAN LK, CHROUSOS GP, KELLNER C et al.: Successful treatment of Cushing's syndrome with the glucocorticoid antagonist RU 486. J. Clin. Endocrinol. Metab. (1985) 61:536-540.
97. SCHULTE HM, CHROUSOS GP, GOLD PW et al.: Continuous administration of synthetic ovine corticotropin-releasing factor in man. Physiological and pathophysiological implications. J. Clin. Invest. (1985) 75:1781-1785.
98. BJORNTORP P, ROSMOND R: Hypothalamic origin of the metabolic syndrome X. Ann. NY Acad. Sci. (1999) 892:297-307.
99. KATSUMATA M, GUPTA C, BAKER MK, SUSSDORF CE, GOLDMAN AS: Diphenylhydantoin: an alternative ligand of a glucocorticoid receptor affecting prostaglandin generation in A/J mice. Science (1982) 218:1313-1315.
100. SCHMIDT TJ, MILLER-DIENER A, LITWACK G: X-lapachone, a specific competitive inhibitor of ligand binding to the glucocorticoid receptor. J. Biol. Chem. (1984) 259:9536-9543.
101. MINER JN, TYREE C, HU J et al.: A nonsteroidal glucocorticoid receptor antagonist. Mol. Endocrinol. (2003) 17(1):117-127.
102. TU N, LINK JT, SORENSEN BK et al.: Bile acid conjugates of a nonsteroidal glucocorticoid receptor modulator. Bioorg. Med. Chem. Lett. (2004) 14:4179-4183.
103. JACOBSON PB, VON GELDERN TW, OHMAN L et al.: Hepatic glucocorticoid receptor antagonism is sufficient to reduce elevated hepatic glucose output and improve glucose control in animal models of Type 2 diabetes. J. Pharmacol. Exp. Ther. (2005) 314(1):191-200.
104. EINSTEIN M, GREENLEE M, ROUEN G et al.: Selective glucocorticoid receptor nonsteroidal ligands completely antagonize the dexamethasone mediated induction of enzymes involved in gluconeogenesis and glutamine metabolism. J. Steroid Biochem. Mol. Biol. (2004) 92:345-356.
105. ROUSSEAU GG, BAXTER JD, TOMKINS GM: Glucocorticoid receptors: relations between steroid binding and biological effects. J. Mol. Biol. (1972) 67:99-115.
106. MARKHAM A, BRYSON HM: Deflazacort. A review of its pharmacological properties and therapeutic efficacy. Drugs (1995) 50:317-333.
107. KROGSGAARD MR, LUND B, JOHNSSON B: A longterm prospective study of the equipotency between deflazacort and prednisolone in the treatment of patients with polymyalgia rheumatica. J. Rheumatol. (1995) 22:1660-1662.
108. CALLEJA C, PASCUSSI JM, MANI JC, MAUREL P, VILAREM MJ: The antibiotic rifampicin is a nonsteroidal ligand and activator of the human glucocorticoid receptor. Nat. Med. (1998) 4:92-96.
109. VISSER J, HILLEBRANDS JL, ROZING J: No evidence that rifampicin has glucocorticoid-like immunosuppressive properties leading to suppression of rat-splenocyte proliferation in vitro. J. Antimicrob. Chemother. (2001) 47:894-895.
110. PROCOPIOU PA, BIGGADIKE K, ENGLISH AF et al.: Novel glucocorticoid antedrugs possessing a 17β-(γ-lactone) ring. J. Med. Chem. (2001) 44:602-612.
111. BODOR N: Recent advances in retrometabolic design approaches. J. Control Release (1999) 62:209-222.
112. BODOR N, VARGA M: Effect of a novel soft steroid on the wound healing of rabbit cornea. Exp. Eye Res. (1990) 50:183-187.
113. METSELAAR JM, WAUBEN MH, WAGENAAR-HILBERS JP, BOERMAN OC, STORM G: Complete remission of experimental arthritis by joint targeting of glucocorticoids with long-circulating liposomes. Arthritis Rheum. (2003) 48:2059-2066.
114. PAUL-CLARK MJ, GILROY DW, WILLIS D, WILLOUGHBY DA, TOMLINSON A: Nitric oxide synthase inhibitors have opposite effects on acute inflammation depending on their route of administration. J. Immunol. (2001) 166:1169-1177.
115. PAUL-CLARK M, DEL SOLDATO P, FIORUCCI S, FLOWER RJ, PERRETTI M: 21-NO-prednisolone is a novel nitric oxide-releasing derivative of prednisolone with enhanced anti-inflammatory properties. Br. J. Pharmacol. (2000) 131:1345-1354.
116. PAUL-CLARK MJ, MANCINI L, DEL SOLDATO P, FLOWER RJ, PERRETTI M: Potent antiarthritic properties of a glucocorticoid derivative, NCX-1015, in an experimental model of arthritis. Proc. Natl. Acad. Sci. USA (2002) 99:1677-1682.
117. ALLAN GF, LENG X, TSAI SY et al.: Hormone and antihormone induce distinct conformational changes which are central to steroid receptor activation. J. Biol. Chem. (1992) 267:19513-19520.
118. FENG W, RIBEIRO RC, WAGNER RL et al.: Hormone-dependent coactivator binding to a hydrophobic cleft on nuclear receptors. Science (1998) 280:1747-1749.
119. APRILETTI JW, RIBEIRO RC, WAGNER RL et al.: Molecular and structural biology of thyroid hormone receptors. Clin. Exp. Pharmacol. Physiol. Suppl. (1998) 25:S2-S11.
120. COSMAN F, LINDSAY R: Selective estrogen receptor modulators: clinical spectrum. Endocr. Rev. (1999) 20:418-434.
121. NEGRO-VILAR A: Selective androgen receptor modulators (SARMs): a novel approach to androgen therapy for the new millennium. J. Clin. Endocrinol. Metab. (1999) 84:3459-3462.
122. McDONNELL DP, NORRIS JD: Analysis of the molecular pharmacology of estrogen receptor agonists and antagonists provides insights into the mechanism of action of estrogen in bone. Osteoporos. Int. (1997) 1(Suppl. 7):S29-S34.
123. TSAI MJ, O'MALLEY BW: Molecular mechanisms of action of steroid/thyroid receptor superfamily members. Ann. Rev. Biochem. (1994) 63:451-486.
124. REICHARDT HM, TRONCHE F, BERGER S, KELLENDONK C, SCHUTZ G: New insights into glucocorticoid and mineralocorticoid signaling: lessons from gene targeting. Adv. Pharmacol. (2000) 47:1-21.
125. VAYSSIERE BM, DUPONT S, CHOQUART A et al.: Synthetic glucocorticoids that dissociate transactivation and AP-1 transrepression exhibit antiinflammatory activity in vivo. Mol. Endocrinol. (1997) 11:1245-255.
126. VANDEN BERGHE W, FRANCESCONI E, DE BOSSCHER K, RESCHE-RIGON M, HAEGEMAN G: Dissociated glucocorticoids with anti-inflammatory potential repress interleukin-6 gene expression by a nuclear factor-κB-dependent mechanism. Mol. Pharmacol. (1999) 56:797-806.
127. BELVISI MG, WICKS SL, BATTRAM CH et al.: Therapeutic benefit of a dissociated glucocorticoid and the relevance of in vitro separation of transrepression from transactivation activity. J. Immunol. (2001) 166:1975-1982.
128. ELMORE SW, PRATT JK, COGHLAN MJ et al.: Differentiation of in vitro transcriptional repression and activation profiles of selective glucocorticoid modulators. Bioorg. Med. Chem. Lett. (2004) 14:1721-1727.
129. LIN CW, NAKANE M, STASHKO M et al.: trans-Activation and repression properties of the novel nonsteroid glucocorticoid receptor ligand 2,5-dihydro-9-hydroxy-10-methoxy-2,2, 4-trimethyl-5-(1-methylcyclohexen-3-y 1)-1H-[1]benzopyrano[3,4-f]quinoline (A276575) and its four stereoisomers. Mol. Pharmacol. (2002) 62:297-303.
130. COGHLAN MJ, JACOBSON PB, LANE B et al.: A novel antiinflammatory maintains glucocorticoid efficacy with reduced side effects. Mol. Endocrinol. (2003) 17:860-869.
131. MINER JN: Designer glucocorticoids. Biochem. Pharmacol. (2002) 64:355-361.
132. SCHACKE H, SCHOTTELIUS A, DOCKE WD et al.: Dissociation of transactivation from transrepression by a selective glucocorticoid receptor agonist leads to separation of therapeutic effects from side effects. Proc. Natl. Acad. Sci. USA (2004) 101:227-232.